• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Let's play "Antibodies for Alzheimers!"

Quote
























It's getting beyond absurd how much money Lilly keeps pouring down the A-beta rabbit hole.

The original mAb patent was filed in 2002 and has now failed 3 trials, but hey, it's on to EXPEDITION 4?

At what point does management wake up and pull the plug?
 








anonymous said:
It's getting beyond absurd how much money Lilly keeps pouring down the A-beta rabbit hole.

The original mAb patent was filed in 2002 and has now failed 3 trials, but hey, it's on to EXPEDITION 4?

At what point does management wake up and pull the plug?
Click to expand...

Some very terrible, horrible horrible people say these trials are all about spoofing Wall Street analysts.

That would never happen here.

But seriously, the company basically walks in lock-step with whatever the latest mantra is (like "Antibodies for Alzheimers") -- look back at the history here- still trying to justify a colossal acquisition mistake. Dissent should be encouraged within the ranks. Do something like Google does, have a couple dozen different subsidiaries, let them run with their pet projects.

I've been studying this area for years. It's basically a matter of addressing a dozen or so different targets, and sorry, there is no single magic bullet, and there never will be.
 




























 




















Top Bottom
Back
Quote